BIOTECH100
A Resource Guide to Investing in Biotechnology
Directory - Encyclopedia - Stock Index - Drugs  

Biotech100 Stock Index

Neorx Corp.

About Neorx Corp

NeoRx Corporation is engaged in the development and commercialization of oncology products. The Company has two clinical-stage product candidates in development: STR (Skeletal Targeted Radiotherapy) and NX 473. STR is a bone-targeting radiopharmaceutical that delivers radiation directly to cancer cells in the bone and marrow. STR is being developed to treat patients with multiple myeloma and other cancers that arise in or spread to the bone marrow.NeoRx is dedicated to the development and commercialization of oncology products. We have two clinical-stage product candidates in development -- STRô and NX 473. Both candidates have been evaluated in cancer patients, demonstrating clinical benefits and manageable safety profiles. STR is a bone-targeting radiopharmaceutical that delivers radiation directly to cancer cells in the bone and marrow. We are developing STR to treat patients with multiple myeloma and other cancers that arise in or spread to the bone marrow, such as leukemias, lymphomas and bone metastases of breast, prostate and lung cancers. We currently are conducting a Phase III pivotal clinical trial of STR with high-dose chemotherapy and autologous (self-donor) stem cell transplantation in patients with multiple myeloma. The study is open to enrollment of patients with primary refractory multiple myeloma. We also have submitted a protocol to the Food and Drug Administration (FDA) for a Phase II study of STR in patients with breast cancer metastasized to the bone. NX 473 is a next-generation platinum compound designed to improve on the safety and efficacy of existing platinum therapeutics for cancer. In early clinical trials, NX 473 has demonstrated clinical activity in patients with lung, prostate and ovarian cancers, as a single agent and in combination regimens. We have received clearance from the FDA for our Investigational New Drug (IND) application for a Phase II study of NX 473 in patients with small cell lung cancer. We also plan to conduct a Phase I/II clinical study of NX 473 in patients with colorectal cancer.

 

 

Product Pipeline for NeoPharm --

LEP ETU Liposomal Paclitaxel-Easy-to-use -- Advanced cancers; including breast, lung and ovarian

 

Clinical Trials for Neorx

 

STR for Multiple Myeloma

NX 473 is a next-generation platinum compound for cancer treatment. It has been tested extensively in preclinical studies, and has been evaluated in more than 500 patients in Phase I and II clinical trials. NX 473 has demonstrated activity as a single agent in patients with lung cancer, ovarian cancer, and hormone refractory prostate cancer,

More on Neorx

Home Page

Key Statistics for NeoPharm

Basic Chart for NeoPharm

Analyst Opinion

Analysts Estimates

NEWS

 
Biotech100 Index
What are the Requirements to be listed in the Biotech100 Index?
See the Biotech100 List

Sponsored Links

Clinical Trials
What is a Clinical Trial?
Phase I ,-- Phase II, -- PhaseIII
What is Randomized Control?
 What is a Double Blind Experiment?
What is the role of the FDA?

 

Key Biotech Terms

 

Biotech Resources

 

Investing in Stocks
Small Cap Stocks
Stocks and Bonds
Biotech100 Index

Careers and Employment
Biotechnology and Pharmaceutical
What are the Fastest Growing Careers?

 

Google
 
Web www.biotech100.com
SEARCH THE BIOTECH100 WEBSITE
  
     

 


Copyright © 2005 BIOTECH100.COM. All rights reserved.

email: info@biotech100.com